Literature DB >> 33710875

A Long Residence Time Enoyl-Reductase Inhibitor Explores an Extended Binding Region with Isoenzyme-Dependent Tautomer Adaptation and Differential Substrate-Binding Loop Closure.

Sandra Eltschkner1,2, Josef Kehrein3, Thien Anh Le4,5, Shabnam Davoodi6, Benjamin Merget3, Sneha Basak6, Jonas D Weinrich1,7, Johannes Schiebel1, Peter J Tonge6, Bernd Engels4, Christoph Sotriffer3, Caroline Kisker1.   

Abstract

The enoyl-acyl carrier protein (ACP) reductase (ENR) is a key enzyme within the bacterial fatty-acid synthesis pathway. It has been demonstrated that small-molecule inhibitors carrying the diphenylether (DPE) scaffold bear a great potential for the development of highly specific and effective drugs against this enzyme class. Interestingly, different substitution patterns of the DPE scaffold have been shown to lead to varying effects on the kinetic and thermodynamic behavior toward ENRs from different organisms. Here, we investigated the effect of a 4'-pyridone substituent in the context of the slow tight-binding inhibitor SKTS1 on the inhibition of the Staphylococcus aureus enoyl-ACP-reductase saFabI and the closely related isoenzyme from Mycobacterium tuberculosis, InhA, and explored a new interaction site of DPE inhibitors within the substrate-binding pocket. Using high-resolution crystal structures of both complexes in combination with molecular dynamics (MD) simulations, kinetic measurements, and quantum mechanical (QM) calculations, we provide evidence that the 4'-pyridone substituent adopts different tautomeric forms when bound to the two ENRs. We furthermore elucidate the structural determinants leading to significant differences in the residence time of SKTS1 on both enzymes.

Entities:  

Keywords:  Mycobacterium tuberculosis; Staphylococcus aureus; diphenylether; enoyl-ACP reductase; residence time; tautomerization

Mesh:

Substances:

Year:  2021        PMID: 33710875      PMCID: PMC8791450          DOI: 10.1021/acsinfecdis.0c00437

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  48 in total

Review 1.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

2.  Reaction paths of tautomerization between hydroxypyridines and pyridones.

Authors:  Noriko Tsuchida; Shinichi Yamabe
Journal:  J Phys Chem A       Date:  2005-03-10       Impact factor: 2.781

3.  Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA.

Authors:  Cheng-Tsung Lai; Huei-Jiun Li; Weixuan Yu; Sonam Shah; Gopal R Bommineni; Victoria Perrone; Miguel Garcia-Diaz; Peter J Tonge; Carlos Simmerling
Journal:  Biochemistry       Date:  2015-07-24       Impact factor: 3.162

4.  The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Authors:  S Escaich; L Prouvensier; M Saccomani; L Durant; M Oxoby; V Gerusz; F Moreau; V Vongsouthi; Kirsty Maher; Ian Morrissey; C Soulama-Mouze
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

5.  Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.

Authors:  Carla Neckles; Sandra Eltschkner; Jason E Cummings; Maria Hirschbeck; Fereidoon Daryaee; Gopal R Bommineni; Zhuo Zhang; Lauren Spagnuolo; Weixuan Yu; Shabnam Davoodi; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  Biochemistry       Date:  2017-03-21       Impact factor: 3.162

6.  Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.

Authors:  R J Heath; C O Rock
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

Review 7.  Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Authors:  Hao Lu; Peter J Tonge
Journal:  Acc Chem Res       Date:  2008-01       Impact factor: 22.384

8.  Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality.

Authors:  Johannes Schiebel; Andrew Chang; Hao Lu; Michael V Baxter; Peter J Tonge; Caroline Kisker
Journal:  Structure       Date:  2012-05-09       Impact factor: 5.006

9.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

Authors:  Dawn M Sievert; James T Rudrik; Jean B Patel; L Clifford McDonald; Melinda J Wilkins; Jeffrey C Hageman
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

Review 10.  Design strategies to address kinetics of drug binding and residence time.

Authors:  Kevin P Cusack; Ying Wang; Michael Z Hoemann; Jasmina Marjanovic; Roland G Heym; Anil Vasudevan
Journal:  Bioorg Med Chem Lett       Date:  2015-03-05       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.